UPLOAD Filing
BriaCell Therapeutics Corp.
Date: June 24, 2025 · CIK: 0001610820 · Accession: 0000000000-25-006592
AI Filing Summary & Sentiment
Reasoning
Letter
Re: BriaCell Therapeutics Corp. Draft Registration Statement on Form S-1 Submitted June 18, 2025 CIK No. 0001610820 Dear William V. Williams:
June 24, 2025
William V. Williams Chief Executive Officer BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1, Canada
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Benasz Hansotia
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 24, 2025 William V. Williams Chief Executive Officer BriaCell Therapeutics Corp. Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1, Canada Re: BriaCell Therapeutics Corp. Draft Registration Statement on Form S-1 Submitted June 18, 2025 CIK No. 0001610820 Dear William V. Williams: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Benasz Hansotia </TEXT> </DOCUMENT>